Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trump FY 2020 Budget Renews Push To Reform 180-Day Exclusivity

Executive Summary

US FDA would get an overall increase in funding under the president's fiscal year 2020 budget proposal, although the generic drug industry opposes reforms targeting the 180-day exclusivity clock for first filers.

Related Content

Biosimilar Pathway Would Disappear If ACA Repealed, Gottlieb Says
Market Forces May Impact GDUFA III Talks
CREATES Act Has a Penalty Problem
Generic Industry Market Forces May Impact GDUFA III Talks
Running The Gauntlet: Takeaways From The First Round Of HHS Hearings In 2019
Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase
US Initiative To End HIV Epidemic Will Boost PrEP Access
How Much Can Trump’s Childhood Cancer Funding Proposal Boost Drug Approvals?
Trump's Budget Surprise: FDA Gains 13% Increase
Trump's Budget Request To Include ANDA Exclusivity Changes





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts